Guidelines for Translational Research in Heart Failure

  • Enrique Lara-Pezzi
  • Philippe Menasché
  • Jean-Hugues Trouvin
  • Lina Badimón
  • John P. A. Ioannidis
  • Joseph C. Wu
  • Joseph A. Hill
  • Walter J. Koch
  • Albert F. De Felice
  • Peter de Waele
  • Valérie Steenwinckel
  • Roger J. Hajjar
  • Andreas M. Zeiher
Article

DOI: 10.1007/s12265-015-9606-8

Cite this article as:
Lara-Pezzi, E., Menasché, P., Trouvin, JH. et al. J. of Cardiovasc. Trans. Res. (2015) 8: 3. doi:10.1007/s12265-015-9606-8

Abstract

Heart failure (HF) remains a major cause of death and hospitalization worldwide. Despite medical advances, the prognosis of HF remains poor and new therapeutic approaches are urgently needed. The development of new therapies for HF is hindered by inappropriate or incomplete preclinical studies. In these guidelines, we present a number of recommendations to enhance similarity between HF animal models and the human condition in order to reduce the chances of failure in subsequent clinical trials. We propose different approaches to address safety as well as efficacy of new therapeutic products. We also propose that good practice rules are followed from the outset so that the chances of eventual approval by regulatory agencies increase. We hope that these guidelines will help improve the translation of results from animal models to humans and thereby contribute to more successful clinical trials and development of new therapies for HF.

Keywords

Guidelines Heart failure Animal models New therapies Preclinical studies Clinical trials Good laboratory practice Induced pluripotent stem cells Toxicity 

Abbreviations

ACE

Angiotensin-converting enzyme

ADME

Absorption, distribution, metabolism, excretion

API

Active pharmacological product

ARB

Angiotensin II receptor blocker

ATMP

Advanced therapy medicinal products

AUC

Area under the curve

CAD

Coronary artery disease

CRISPR

Clustered regularly interspaced short palindromic repeats

DCM

Dilated cardiomyopathy

EMA

European Medicines Agency

FDA

Food and Drug Administration

GLP

Good laboratory practice

GMP

Good manufacturing practice

HF

Heart failure

HFpEF

Heart failure with preserved ejection fraction

INDs

Investigational new drugs

LAD

Left anterior descending

LV

Left ventricle

MA

Market authorization

MI

Myocardial infarction

NOAEL

No observed adverse effect level

PCI

Percutaneous coronary intervention

PD

Pharmacodynamic

PDE

Phosphodiesterase

PES

Programmed electrical stimulation

POC

Proof of concept

SOC

Standard of care

TAC

Transverse aortic constriction

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Enrique Lara-Pezzi
    • 1
  • Philippe Menasché
    • 2
  • Jean-Hugues Trouvin
    • 3
    • 4
  • Lina Badimón
    • 5
  • John P. A. Ioannidis
    • 6
  • Joseph C. Wu
    • 7
  • Joseph A. Hill
    • 8
    • 14
  • Walter J. Koch
    • 9
  • Albert F. De Felice
    • 10
  • Peter de Waele
    • 11
  • Valérie Steenwinckel
    • 11
  • Roger J. Hajjar
    • 12
  • Andreas M. Zeiher
    • 13
  1. 1.Cardiovascular Development and Repair DepartmentCentro Nacional de Investigaciones Cardiovasculares (CNIC)MadridSpain
  2. 2.Assistance Publique-Hôpitaux de ParisHôpital Européen Georges Pompidou Department of Cardiovascular SurgeryParisFrance
  3. 3.School of Pharmacy, Department on Health Security and Public HealthUniversity Paris Sorbonne CitéParisFrance
  4. 4.Committee for Advanced Therapies, European Medicines AgencyLondonUK
  5. 5.Cardiovascular Research Center (CSIC-ICCC)Hospital de la Santa Creu i Sant-Pau (IIB-Sant Pau)BarcelonaSpain
  6. 6.Stanford Prevention Research Center, Department of Medicine and Division of Epidemiology, Department of Health Research and PolicyStanford UniversityStanfordUSA
  7. 7.Stanford Cardiovascular Institute, School of MedicineStanford UniversityStanfordUSA
  8. 8.Department of Internal Medicine (Cardiology)University of Texas Southwestern Medical CenterDallasUSA
  9. 9.Department of Pharmacology, Center for Translational MedicineTemple UniversityPhiladelphiaUSA
  10. 10.Division of Cardiovascular Drug ProductsUS Food and Drug AdministrationSilver SpringUSA
  11. 11.Cardio3 BioSciences S.A.Mont-Saint-GuibertFrance
  12. 12.Cardiovascular Research Center, Department of CardiologyMount Sinai School of MedicineNew YorkUSA
  13. 13.Department of Cardiology, Internal Medicine IIIJ. W. Goethe University Hospital FrankfurtFrankfurt am MainGermany
  14. 14.Department of Molecular BiologyUniversity of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations